FIELD: intestinal diseases. SUBSTANCE: treatment is effected by introducing therapeutically active substance: anti-adhesive antibody or its fragment. Antibody is selected from the group including anti-CD18 and anti-ICAM-1 antibodies, the former being preferably monoclonal R 15.7 antibody and the latter monoclonal R 6.5 antibody. Antibody is introduced intravenously in amounts from 0.1 to 10 mg/kg. Above-mentioned fragment may be Fab or F(ab)2 fragment of anti-adhesive antibody. EFFECT: simplified procedure and enhanced its efficiency. 6 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF ANTIBODY FRAGMENT IN THERAPY | 1994 |
|
RU2139092C1 |
| HYBRIDOMA DESIGNATES AS 199M AND MONOCLONAL ANTIBODY SECRETED BY THIS HYBRIDOMA | 1997 |
|
RU2183671C2 |
| ANTI-MIF ANTIBODIES | 2008 |
|
RU2509777C2 |
| ANTIBODY VFF-18 AND ITS ANALOGUES | 1995 |
|
RU2204606C2 |
| APPLICATION OF SINGLE DOSE OF CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2421242C2 |
| HUMAN IMMUNOGLOBULIN SHOWING SPECIFICITY TO HUMAN PROTEIN L-SELECTIN | 1993 |
|
RU2151612C1 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| HIGH-AFFINITY HUMAN ANGIOPOIETIN-2 ANTIBODIES | 2010 |
|
RU2545399C2 |
| APPLICATION OF HEPARIN-BINDING ANTAGONISTS IN INHIBITING BRADYKININ RELEASING | 2000 |
|
RU2251433C2 |
